-
Published 8/7/2025
Barry A, England BR, Sayles H, Helget LN, Androsenko M, Wu H, Michaud K, Kramer B, Newcomb JA, Brophy MT, Davis-Karim A, Ferguson R, Pillinger MH, Neogi T, Palevsky PM, O'Dell JR, Mikuls TR. Improvements in Health-Related Quality of Life with Treat-to-Target Urate-Lowering Therapy in Gout: A Post-hoc Analysis of a Randomized Multicenter Trial. Arthritis Care Res (Hoboken). 2025 Aug 07. PMID: 40771143.
-
Published 8/5/2025
Kohn S, Sayles H, Helget LN, England BR, Roul P, Newcomb JA, Kramer B, Davis-Karim A, Brophy MT, Ferguson R, Pillinger MH, Neogi T, Palevsky PM, Wu H, O'Dell JR, Mikuls TR. Real-world persistence of urate-lowering therapy following a treat-to-target intervention: A two-year follow-up analysis of the STOP gout trial. Semin Arthritis Rheum. 2025 Oct; 74:152800. PMID: 40782426.
-
Published 6/7/2025
Kim DY, Huhmann L, Hippe DS, Wheless L, Pavlis M, Hwang JC, Brophy MT, Do NV, Nghiem P, Fillmore N, Hartman RI. Treatment and disease-specific survival differences among veterans with Merkel cell carcinoma. J Am Acad Dermatol. 2025 Oct; 93(4):1103-1106. PMID: 40490100.
-
Published 6/1/2025
Moncayo AK, Ferguson JM, Dizon MP, Huhmann L, Kim DY, Do N, Brophy MT, Osborne TF, Spence AC, Fillmore NR, Swetter SM, Hartman RI. Area Deprivation Index and Melanoma Thickness in Veterans. JAMA Dermatol. 2025 Jun 01; 161(6):582-588. PMID: 40047783.
-
Published 4/8/2025
Lee MH, La J, Brophy MT, Do NV, Edwards CV, DuMontier C, Hobbs GS, Fillmore NR. Psychiatric and substance use disorders predict poor outcomes in older veterans with acute myeloid leukemia. Blood Adv. 2025 Apr 08; 9(7):1555-1558. PMID: 39715463.